坪田ラボ announced that it had entered into a joint research agreement with ファルストマ on eye drops using ultrafine bubble water. The companies aim to formulate drugs that have been difficult to turn into eye drops using conventional technologies by leveraging the properties of high-concentration UFB water, with a view to developing new ophthalmic drugs.
坪田ラボ and ファルストマ entered into a joint research agreement aimed at developing eye drops using ultrafine bubble water. The agreement was announced after trading ended on the 7th, and the stock's upside remained limited despite a buying-led start.
The research will leverage the dispersion and solubilization properties of high-concentration UFB water to formulate drugs that have been difficult to turn into eye drops using conventional technologies, as well as to create eye-drop products based on new concepts.
The two companies plan to combine their technologies and expertise to advance the development of new pharmaceuticals in the ophthalmic field.